NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C

CompletedPhase 3

Sponsor: ANRS, Emerging Infectious Diseases

Conditions: Hepatitis C, Chronic

Interventions: Irbesartan, placebo

Countries: France

The purpose of this study is to examine the efficacy of irbesartan on the progression of liver fibrosis in adult patients with chronic hepatitis C. The expected total enrollment is 200 patients. Patients who meet the study criteria and accept to participate at this study will take by day one tablet of 150 mg of treatment (irbesartan or placebo) during two years. The assessment of efficacy will be make by evaluation of area of liver fibrosis and blood markers of liver fibrosis

Eligibility overview

Sex: ALL

Age: 18 Years to 75 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* age between 18 and 75 years
* liver biopsy performed (less 18 month before inclusion), fibrosis score F2,F3 or F3+ in Metavir classification,
* patients without antiviral therapy
* contraindication to anti viral treatment
* non responders or relapsers patients to past antiviral treatment

Exclusion Criteria:

* hepatocellular carcinoma
* HIV
* alcool abuser
* cirrhosis
* anti-fibrotic treatment
* pregnancy or breast feeding

Locations (1)

Angers, France